Nomura Holdings Inc. Takes $463,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Nomura Holdings Inc. acquired a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,690 shares of the company’s stock, valued at approximately $463,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SWTX. Seven Eight Capital LP acquired a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth approximately $1,544,000. Perceptive Advisors LLC lifted its position in SpringWorks Therapeutics by 28.7% in the fourth quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock worth $71,439,000 after purchasing an additional 436,830 shares during the period. Point72 Asset Management L.P. boosted its stake in SpringWorks Therapeutics by 310.7% during the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock valued at $78,919,000 after purchasing an additional 1,635,722 shares in the last quarter. Norges Bank acquired a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at $12,331,000. Finally, Monashee Investment Management LLC bought a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth $2,699,000.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SWTX. JPMorgan Chase & Co. raised their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $75.00 price objective (up previously from $70.00) on shares of SpringWorks Therapeutics in a research note on Thursday, May 2nd. Barclays increased their target price on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Finally, HC Wainwright restated a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a report on Friday, May 31st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $68.83.

SpringWorks Therapeutics Stock Performance

NASDAQ SWTX opened at $36.12 on Friday. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92. The stock’s 50-day moving average price is $41.97 and its two-hundred day moving average price is $42.93.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The company had revenue of $21.00 million for the quarter, compared to analyst estimates of $12.07 million. During the same period in the previous year, the business posted ($1.18) EPS. The business’s quarterly revenue was up 2000.0% compared to the same quarter last year. As a group, equities analysts expect that SpringWorks Therapeutics, Inc. will post -4.62 earnings per share for the current fiscal year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.